A new blood test was found to detect colon cancer with more than 80% accuracy — and to rule it out for 90% of healthy people.

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Precision oncology is a cancer treatment approach that considers individual genetics, environmental exposures, and lifestyle factors to tailor the most ...

Fake papers are contaminating the world’s scientific literature, fueling a corrupt industry and slowing legitimate lifesaving ...

The oncologist was studying a sequence of chemical reactions ... “We pay them for accepting papers,” said Bodo Stern, a ...

Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...

John Phillips, M.D., FACS John Phillips, M.D., FACS, has been named chair of the Department of Urology at New York ...

Over the past decade, furtive commercial entities around the world have industrialized the production, sale and dissemination ...

Taking 160 milligrams of aspirin a day cuts the risk of cancer recurrence in half among colon cancer patients with a mutation ...

The blood test was 81% accurate in detecting colon cancer among people who have the disease, researchers reported at the 2025 ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...